Expert brokerage guidance for CLIA-certified labs, reference laboratories, and specialty diagnostics companies in the $1M–$5M revenue range.
Find Lab & Diagnostics Company Deals Without a BrokerSelling or acquiring a clinical laboratory requires a broker who understands CLIA compliance, payer contract assignment, and reimbursement dynamics. The right advisor navigates regulatory complexity, positions your lab's specialty testing capabilities, and connects you with qualified healthcare buyers or sellers.
Specialized advisory firms focused exclusively on healthcare services, including labs, diagnostics, and pathology practices. Deep expertise in payer contracts, CLIA transitions, and regulatory due diligence.
Best for: Sellers with $2M+ revenue seeking PE-backed acquirers or strategic lab roll-up platforms requiring sophisticated deal structuring.
Generalist brokers experienced in SBA 7(a) loan-eligible transactions who understand lender requirements, working capital needs, and buyer qualification for lower middle market labs.
Best for: First-time buyers using SBA financing to acquire a small independent lab or toxicology practice under $3M in revenue.
Full-service M&A advisors running structured auction processes for larger diagnostics platforms, attracting institutional buyers including private equity and hospital systems.
Best for: Lab owners with $3M–$5M+ revenue, strong EBITDA margins, and specialty assay capabilities seeking maximum valuation through competitive bidding.
Skip the broker — find deals direct
DealFlow OS surfaces off-market Lab & Diagnostics Company targets with seller signals and outreach angles. No commission.
How many clinical laboratory or diagnostics businesses have you closed in the past three years, and what were the revenue ranges?
Lab transactions require CLIA compliance knowledge and payer contract expertise. Generic brokers without healthcare deals often mishandle regulatory transfer requirements.
How do you handle payer contract assignment and CLIA license transfer during the ownership transition process?
Mismanaged payer contract assignments or CLIA lapses can halt revenue post-close, making broker familiarity with these processes critical.
What buyer types are in your active network for laboratory acquisitions — PE firms, hospital systems, or individual operators?
Lab buyers are a narrow universe. Brokers without established relationships waste time and expose your business to unqualified buyers.
How do you normalize EBITDA for labs with owner compensation, medical director fees, and facility arrangements embedded in the financials?
Lab financial statements often obscure true earnings. Improper add-backs reduce valuation or trigger buyer skepticism during due diligence.
Independent labs typically sell for 3.5x–6.5x EBITDA. Specialty or esoteric testing capabilities, CAP accreditation, and diversified referral sources drive valuations toward the higher end.
Yes. CLIA-certified labs are SBA-eligible businesses. Buyers need clean compliance history, sufficient working capital, and lender comfort with payer contract continuity post-acquisition.
Most independent lab sales take 12–24 months from preparation to close, driven by regulatory transfer timelines, payer contract assignments, and buyer due diligence on billing compliance.
CAP accreditation, diversified test menus with specialty assays, multiple referring provider relationships, clean OIG history, and strong revenue cycle metrics all meaningfully increase buyer interest and valuation.
More Lab & Diagnostics Company Guides
Find Brokers in Other Industries
DealFlow OS surfaces off-market targets, scores seller motivation, and writes your outreach. Free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers